No doubt. I'm not surprised that administration is proving difficult, but 5-20% is beyond abysmal... add to that that hospitals are turning mild/moderate people away, the only population that these virus-targeting MABs could hope to help, until they are beyond the initial stages, and those MABs will no longer be much use.

Insanity.

Quote:

---

Another challenge is that the antibody drugs have to be given to patients soon after they contract COVID-19. Timing is everything. If patients aren’t getting tested or don’t get test results back within a short window after they fall ill, they can’t benefit from the drug. Even if they do get diagnosed with COVID-19 quickly at a testing site, they may not start to feel seriously ill or call a doctor until they’re outside that window. Without that contact, they might not know about or be offered the drug.

In addition, the drug has to be given intravenously — so patients who are in the early, most contagious stages of their disease have to go to a hospital or outpatient facility where they will interact with nurses and doctors. States and health care organizations have to set up safe places for patients to receive the treatment.

---